A Recurrent De Novo Mutation In Kcnc1 Causes Progressive Myoclonus Epilepsy
Göster/ Aç
Tarih
2015Yazar
Muona, Mikko
Berkovic, Samuel F.
Dibbens, Leanne M.
Oliver, Karen L.
Maljevic, Snezana
Bayly, Marta A.
Joensuu, Tarja
Canafoglia, Laura
Franceschetti, Silvana
Michelucci, Roberto
Markkinen, Salla
Heron, Sarah E.
Hildebrand, Michael S.
Andermann, Eva
Andermann, Frederick
Gambardella, Antonio
Tinuper, Paolo
Licchetta, Laura
Scheffer, Ingrid E.
Criscuolo, Chiara
Filla, Alessandro
Ferlazzo, Edoardo
Ahmad, Jamil
Ahmad, Adeel
Baykan, Betul
Said, Edith
Topcu, Meral
Riguzzi, Patrizia
King, Mary D.
Ozkara, Cigdem
Andrade, Danielle M.
Engelsen, Bernt A.
Crespel, Arielle
Lindenau, Matthias
Lohmann, Ebba
Saletti, Veronica
Massano, Joao
Privitera, Michael
Espay, Alberto J.
Kauffmann, Birgit
Duchowny, Michael
Moller, Rikke S.
Straussberg, Rachel
Afawi, Zaid
Ben-Zeev, Bruria
Samocha, Kaitlin E.
Daly, Mark J.
Petrou, Steven
Lerche, Holger
Palotie, Aarno
Lehesjoki, Anna-Elina
Üst veri
Tüm öğe kaydını gösterÖzet
Progressive myoclonus epilepsies (PMEs) are a group of rare, inherited disorders manifesting with action myoclonus, tonicclonic seizures and ataxia. We sequenced the exomes of 84 unrelated individuals with PME of unknown cause and molecularly solved 26 cases (31%). Remarkably, a recurrent de novo mutation, c. 959G>A (p.Arg320His), in KCNC1 was identified as a new major cause for PME. Eleven unrelated exome-sequenced (13%) and two affected individuals in a secondary cohort (7%) had this mutation. KCNC1 encodes K(V)3.1, a subunit of the K(V)3 voltage-gated potassium ion channels, which are major determinants of high-frequency neuronal firing. Functional analysis of the Arg320His mutant channel showed a dominant-negative loss-of-function effect. Ten cases had pathogenic mutations in known PME-associated genes (NEU1, NHLRC1, AFG3L2, EPM2A, CLN6 and SERPINI1). Identification of mutations in PRNP, SACS and TBC1D24 expand their phenotypic spectra to PME. These findings provide insights into the molecular genetic basis of PME and show the role of de novo mutations in this disease entity.